Page results
-
Alison Clements, head of operations, patient flow and EPRR, has received a medal in recognition of her work to support NHS preparations for the Coronation of Charles III and Camilla last May.
-
This page is for parents, carers and family members who are acting as comforters and carers for children and young people having radioactive iodine (131I) treatment. It explains what the treatment involves, how to prepare for it and what you can expect afterwards.
-
UCLH Charity is delighted to announce that the Dangoor Family’s Exilarch’s Foundation has pledged a £1.2m gift to support the next phase of the development of the CAR T programme at University College London Hospitals NHS Foundation Trust (UCLH). The CAR T Speed Release Project aims to reduce the time between extracting patient’s stem cells and injecting re-engineered CAR T cells back into patients with cancer to fight cancer cells.
-
This booklet tells you about having a Vortex® Port-a-cath Insertion (implantable port) with the Interventional Radiology team.
-
UCLH is to work in partnership with University Hospitals Birmingham NHS Foundation Trust in a major digital health initiative in which researchers use data collected in acute care settings to improve patient care.
-
This page tells you about having a PICC (Peripherally Inserted Central Catheter) line insertion with the Interventional Radiology team.
-
This page tells you about having a Non-Tunnelled CVC Line Insertion (Vascath). This page is for those patients who have been referred to Interventional Radiology.
-
A drug commonly used to treat cystic fibrosis improved outcomes for patients with severe COVID-19 pneumonia and could be used to treat other respiratory infections, according to clinical trial results from researchers at UCLH, UCL and the Francis Crick Institute.
-
Patient information for Red Cell Network patients
-
Temporary change to HIV confirmation pathway due to Bio-Rad kit supply issues
File results
-
FOI/2022/0214 - Prostate Cancer (Summary Funding and costs of Xtandi (Enzalutamide) trial: NCT00974311) Xtandi (Enzalutamide) trial, NCT00974311
-
FOI/2022/0217 - Medications for dermatological conditions
-
FOI/2022/0221 - Asthma medications
-
FOI/2022/0223 - Policies/ procedures for management of patients with chest pain
-
FOI/2022/0224 - Procurement for physiotherapy, occupational therapy, pharmacy, radiography, speech and language therapy and sterile services
-
FOI/2022/0226 - Treatments for Haemophilia A
-
FOI/2022/0227 - Number of cancer trackers and cancer MDT co-ordinators at Trust
-
FOI/2022/0230 - Fabry, Gaucher and Pompe diseases drug treatments
-
FOI/2022/0232 - Number of patients who have died while waiting for elective care
-
FOI/2022/0233 - Diagnosis/ treatment of epilepsy, dravet syndrome, lennox gastaut syndrome and tuberous sclerosis complex